Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
Executive summary: Pomerantz LLP filed a class action lawsuit against ADMA Biologics Inc. (NASDAQ: ADMA) on August 6, 2026, alleging securities fraud based on misrepresentations of financial condition and revenue, with a lead plaintiff deadline of August 10, 2026. The lawsuit adds to a pattern of legal actions against ADMA Biologics, increasing regulatory and reputational risk, potentially affecting investor confidence and stock volatility in the biotech sector.
Who is involved: Pomerantz LLP (plaintiffs' counsel), ADMA Biologics Inc. (defendant), investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 (class period), and lead plaintiff applicants.
Likely next: Investors must seek lead plaintiff status by August 10, 2026; if appointed, the case will proceed to discovery, with potential settlement or trial thereafter; ADMA may file a motion to dismiss or respond to the complaint.
On August 6, 2026, Pomerantz LLP announced a class action lawsuit against ADMA Biologics Inc. (NASDAQ: ADMA) on behalf of investors who suffered losses. The lawsuit alleges misrepresentations regarding the company's financial condition and revenue, with a lead plaintiff deadline of August 10, 2026. This follows multiple prior alerts from Hagens Berman and Rosen Law Firm regarding the same securities fraud claims, indicating a sustained legal challenge to ADMA's disclosures. The filing reflects ongoing scrutiny of biotech firms' financial reporting in the post-2024 market environment.
What's next — scenarios
Litigation Attrition (Base Case) (55%)
Prolonged legal expenses and management distraction lead to stagnant stock price volatility.
- Motion to dismiss filing by ADMA
- Appointment of lead plaintiff
Regulatory Escalation (Downside) (30%)
Potential SEC investigation triggered by class action findings, severely limiting R&D capital.
- Formal SEC inquiry announcement
- Material weakness disclosure in quarterly filing
Investor Confidence Recovery (Upside) (15%)
Settlement or dismissal leads to rapid re-rating of revenue quality and stock rally.
- Lawsuit dismissal
- Positive audit verification of revenue streams
What to watch
- August 10, 2026: Deadline for lead plaintiff appointment
- Q3 2026 earnings call for revenue reconciliation commentary
- Q4 2026 10-K filing for updated legal contingency reserves
Timeline
- — INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA (PR Newswire)
- — ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
- — ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- August 10, 2026: Deadline for investors to apply for lead plaintiff status in the Pomerantz class action against ADMA Biologics
- September 2026: Expected deadline for ADMA Biologics to respond to the class action complaint
- Q4 2026: Potential settlement negotiations or motion to dismiss hearing
- Early 2027: Discovery phase likely to begin if case proceeds
Sectors affected
- Biotechnology
- Biologics manufacturing
- Specialty pharmaceuticals
- Investor rights litigation
Regulatory implications
- Increased scrutiny under Securities Exchange Act of 1934 Section 10(b) and Rule 10b-5 for financial disclosures
- Potential SEC investigation into ADMA's revenue recognition and financial reporting practices
- Heightened disclosure expectations for biotech firms with early-stage commercial products
Historical parallels
- Seagen Inc. securities class action (2021) over alleged misrepresentations of drug pipeline progress
- Blueprint Medicines Corp. class action (2020) regarding misleading statements about cancer drug efficacy
- ADMA Biologics prior alerts from Hagens Berman (August 4 and 6, 2026) and Rosen Law Firm (August 6, 2026) on identical allegations
Key entities
Sources
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA — PR Newswire
- ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit — PR Newswire
- ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit — PR Newswire
- ADMA Biologics, Inc. Deadline: ADMA Investors with Losses in Excess of $100K Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm — PR Newswire
Related cases
- AST SpaceMobile faces potential class action lawsuit as law firms seek lead plaintiffs for investor losses
- Securities fraud class action lawsuit initiated against AST SpaceMobile (ASTS)
- Securities fraud class action lawsuit filed against Dick's Sporting Goods (DKS)
- Edelson Lechtzin LLP launches investigation into L3Harris Technologies over alleged misleading business disclosures
- Pomerantz LLP is investigating potential securities claims on behalf of Rent the Runway investors
- Pomerantz Law Firm Launches Investor Investigation into Corning Incorporated Over Potential Securities Claims